Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pretransplantation MRD in Older Patients With AML After Treatment With Decitabine or Conventional Chemotherapy.
Hilberink JR, Morsink LM, van der Velden WJFM, Mulder AB, Hazenberg CLE, de Groot M, Choi G, Schuringa JJ, Meijer K, Blijlevens NMA, Ammatuna E, Huls G. Hilberink JR, et al. Among authors: hazenberg cle. Transplant Cell Ther. 2021 Mar;27(3):246-252. doi: 10.1016/j.jtct.2020.12.014. Epub 2020 Dec 17. Transplant Cell Ther. 2021. PMID: 33781523 Free article.
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, Theobald M, Graux C, Kuball J, Schouten HC, Pabst T, Löwenberg B, Ossenkoppele G, Vellenga E, Cornelissen JJ; HOVON and SAKK Leukemia Groups. Versluis J, et al. Lancet Haematol. 2015 Oct;2(10):e427-36. doi: 10.1016/S2352-3026(15)00148-9. Epub 2015 Sep 18. Lancet Haematol. 2015. PMID: 26686044
Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.
Hilberink J, Hazenberg C, van den Berg E, Mulder A, Schuringa JJ, van der Helm L, de Groot M, Choi G, de Bock GH, Vellenga E, Ammatuna E, Huls G. Hilberink J, et al. Leuk Res. 2019 May;80:33-39. doi: 10.1016/j.leukres.2019.03.004. Epub 2019 Mar 18. Leuk Res. 2019. PMID: 30954622 Free article. Clinical Trial.
Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data.
Weverling F, Roeven M, Nijssen C, Broers AEC, Dovern E, van Rhenen A, Sluis GV, Hazenberg CLE, Balen PV, Kuipers MT, de Vooght KMK, Morsink L, Kuball J, Nur E, de Witte MA. Weverling F, et al. Among authors: hazenberg cle. Blood Adv. 2024 Apr 9;8(7):1683-1686. doi: 10.1182/bloodadvances.2023011190. Blood Adv. 2024. PMID: 38231018 Free PMC article. No abstract available.
Improved Outcome of Allogeneic Transplantation in Older Patients Treated for Myeloid Malignancies Using Post-Transplantation Cyclophosphamide and Reduced Duration of Immune Suppression.
Morsink LM, Hazenberg CLE, Choi G, de Groot MR, Biswana A, Bellido M, Kooistra HAM, Bungener LB, Meijer K, Mulder AB, Huls G. Morsink LM, et al. Among authors: hazenberg cle. Transplant Cell Ther. 2024 Aug;30(8):794-807. doi: 10.1016/j.jtct.2024.05.009. Epub 2024 May 11. Transplant Cell Ther. 2024. PMID: 38740138 Free article.
14 results